ClinicalTrials.gg
CompletedNCT02933658Updated Oct 14, 2016

Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers

A Phase 1 interventional study of Telmisartan and Amlodipine in Hypertension and Dyslipidemia, sponsored by Daewon Pharmaceutical Co., Ltd.. Completed. Open to male participants aged 19 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-14.

Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Non-randomized
Ages
19 Years to 49 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
69th of 99
71 · median 184
Started
2015
with 3 others
Phase 1
15 of 99
none open now
Registered
77th of 99
by date
Lead sponsor
2 of 99
Daewon Pharmaceutical Co., Ltd.

Among the 99 studies testing telmisartan in Hypertension, this one is the 69th largest by enrollment, is one of 4 that started in 2015, is one of 15 in phase 1, and was the 77th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years to 49 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

A non-randomized, two-arm, single-sequence, crossover, open label, multiple oral dosing clinical trial to evaluate the safety and the pharmacokinetic drug-drug interaction of Telmisartan/Amlodipine and Rosuvastatin in healthy male volunteers

03

Conditions studied

  • Hypertension and Dyslipidemia
04

Who can participate

Ages eligible
19 Years to 49 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male who are ≥19, \<50 years old
  • Man who weights over 55kg and whose is 18\~30(kg/m2)
  • Man who doesn't have any chronic disease or history of disease

Exclusion criteria

Exclusion Criteria:

  • man who has or had any disease of liver, kidney, nervous/respiratory/musculoskeletal/cardiovascular/hemato-oncology system or neuropsychiatry
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Reference1

    single(Reference1) -\> combination(Reference1+Reference2)

    Drug: Telmisartan · Drug: Amlodipine · Drug: Rosuvastatin

  • Experimental
    Reference2

    single(Reference2) -\> combination(Reference1+Reference2)

    Drug: Telmisartan · Drug: Amlodipine · Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. AUC of Reference 1

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24hour

  2. Cmax of Reference 1

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24hour

  3. AUC of Reference 2

    Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24hour

  4. Cmax of Reference 2

    Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24hour

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015 and a primary completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2016
First posted
Oct 14, 2016
Start
Nov 2015
Primary completionActual
Nov 2015
Last update
Oct 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02933658
Responsible party
Sponsor
First posted
Oct 14, 2016
Start date
Nov 2015
Primary completion
Nov 2015
Last update
Oct 14, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Amlodipine · Rosuvastatin

Start the discussion